New OCT technique in Parkinson's disease.

Gepubliceerd: 08-12-2014 Laatst bijgewerkt: 15-05-2024

The Retinal Nerve Fiber Layer attenuation coefficient (RNFL-ac) in patients with Parkinson's disease differs significantly from the RNFL-ac in healthy controls.

Ethische beoordeling	Positief advies
Status	Anders
Type aandoening	-
Onderzoekstype	-

Samenvatting

ID

NL-OMON29318

Bron
NTR

Aandoening

English:
- retinal nerve fiber layer
- optical coherence tomography
- Parkinson's disease

In het Nederlands:
- netvlies
- optical coherence tomografie
- de ziekte van Parkinson

Ondersteuning

Primaire sponsor: VU Medical Center
Overige ondersteuning: Stichting Parkinson Fonds

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The primary objective is to investigate if the RNFL-ac in PD patients differs significantly from the RNFL-ac in healthy controls.

Toelichting onderzoek

Achtergrond van het onderzoek

Rationale: Parkinson’s disease (PD) is now known to also cause retinal atrophy. Measuring the retinal never fiber layer attenuation coefficient (RNFL-ac) by means of optical coherence tomography (OCT) is a new technique to analyze the scattering properties of the retina as a sensitive measure of retinal atrophy. Using OCT-derived RNFL-ac it might be possible to differentiate PD patients from healthy subjects.
Objectives: The primary objective is to investigate if the RNFL-ac in PD patients differs significantly from the RNFL-ac in healthy controls.
Secondary Objectives are: 1) to investigate if the RNFL-ac can be used to differentiate PD patients from healthy controls. 2) to compare the sensitivity and specificity of the RNFL-ac with RNFL thickness in differentiating PD patients from healthy controls. 3) to investigate local differences in the RNFL-ac of the retina.
Study design: This is a pilot study with an observational cross-sectional design. Patients and controls will be subjected to a clinical neurological exam and a non-invasive ophthalmologic exam consisting of a visual acuity test (with a Snellen chart), an ocular pressure measurement, a slit lamp examination, fundoscopy and OCT (the RNFL-ac can be calculated from OCT data). The study protocol will take one hour and 20 minutes.
Study population: The study population consists of 20 PD patients in (modified) Hoehn and Yahr stage 2 – 4, age 50 - 70 years, recruited from the outpatient clinic of the Sint Lucas Andreas Ziekenhuis (SLAZ) and 20 adult healthy controls, matched for age, sex and ethnicity.
Main study parameters/endpoints: The main study parameter is the RNFL-ac and its association with the presence of PD will be investigated.

Doel van het onderzoek

The Retinal Nerve Fiber Layer attenuation coefficient (RNFL-ac) in patients with Parkinson's disease differs significantly from the RNFL-ac in healthy controls.

Onderzoeksopzet

End date: 1-jun-2015

Onderzoeksproduct en/of interventie

None

Contactpersonen

Publiek

Neurology department, Sint Lucas Andreas Ziekenhuis

F. Visser
Amsterdam
The Netherlands

Wetenschappelijk

Neurology department, Sint Lucas Andreas Ziekenhuis

F. Visser
Amsterdam
The Netherlands

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

- Clinical diagnosis of PD fulfilling the criteria of the UK PD Brain Bank (Appendix B)

- (modified) Hoehn and Yahr stage 2 – 4 (Appendix C) and a follow up of at least three years after diagnosis of PD.

- Age 50 – 70 years

- Best-corrected vision 20/30 or higher (using a Snellen chart)

- Intra-ocular pressure < 21 mmHg to rule out glaucoma

In order to be eligible to participate in this study, a control subject must meet all of the following criteria:

- Best-corrected vision 20/30 or higher (using a Snellen chart)

- Intra-ocular pressure < 21 mmHg to rule out glaucoma

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Media opacifications

- Concomitant ocular disease (glaucoma, retinal pathology, or pathology of the cornea, lens or optic nerve)

- History of ocular trauma

- History of laser therapy

- Degenerative neurological disease other than PD.

- MMSE < 26 in healthy controls (this is a possible indication of a degenerative neurological disease)

- First degree relative with PD

Onderzoeksopzet

Opzet

Onderzoeksmodel: Anders
Controle: N.v.t. / onbekend

Deelname

Nederland

Status:	Anders
(Verwachte) startdatum:	13-12-2014
Aantal proefpersonen:	40
Type:	Onbekend

Ethische beoordeling

Positief advies

Datum:	08-12-2014
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 44886
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL4901
NTR-old	NTR5003
CCMO	NL47617.029.14
OMON	NL-OMON44886

Resultaten